Folotyn for Non-Hodgkin's Lymphoma Alexandria VA

The drug Folotyn (pralatrexate) has been approved to treat Peripheral T-cell Lymphoma (PTCL), an often aggressive form of non-Hodgkin's lymphoma, the U.S. Food and Drug Administration said Friday. The drug, given accelerated approval because it treats an unmet medical need, was sanctioned for people whose disease has returned or hasn't responded to other types of chemotherapy, the agency said in a news release.

STE 400
(703) 280-5390
8503 Arlington Blvd
Fairfax, VA
Business
Fairfax Northern Virginia Hematology & Oncolo
Specialties
Oncology

Data Provided by:
Stephen Joshua M Banks, MD
(703) 504-7900
4320 Seminary Rd
Alexandria, VA
Specialties
Oncology (Cancer), Radiation Oncology
Gender
Male
Education
Medical School: Stanford Univ Sch Of Med, Stanford Ca 94305
Graduation Year: 1993

Data Provided by:
Winston Ueno
(703) 823-5322
4660 Kenmore Ave
Alexandria, VA
Specialty
Hematology / Oncology

Data Provided by:
Winston Mizuo Ueno, MD
(703) 823-5322
4660 Kenmore Ave Ste 1018
Alexandria, VA
Specialties
Oncology (Cancer), Hematology-Internal Medicine
Gender
Male
Education
Medical School: Creighton Univ Sch Of Med, Omaha Ne 68178
Graduation Year: 1966
Hospital
Hospital: Inova Alexandria Hospital, Alexandria, Va
Group Practice: Fairfax Northern Virginia Hematology Oncology Alexandria

Data Provided by:
Peter Francis, MD
(703) 823-5322
4660 Kenmore Ave Ste 1018
Alexandria, VA
Specialties
Oncology (Cancer), Infectious Diseases
Gender
Male
Education
Medical School: New York Univ Sch Of Med, New York Ny 10016
Graduation Year: 1985

Data Provided by:
Jane Grayson
(703) 504-7900
4320 Seminary Rd
Alexandria, VA
Specialty
Radiation Oncology

Data Provided by:
Jane Grayson, MD
(703) 504-7900
4320 Seminary Rd
Alexandria, VA
Specialties
Oncology (Cancer), Radiation Oncology
Gender
Female
Education
Medical School: Harvard Med Sch, Boston Ma 02115
Graduation Year: 1973
Hospital
Hospital: Inova Alexandria Hospital, Alexandria, Va
Group Practice: Inova Alexandria Cancer Ctr

Data Provided by:
Peter Francis
(703) 823-5322
4660 Kenmore Ave
Alexandria, VA
Specialty
Medical Oncology

Data Provided by:
Robert F Dobrzynski, MD
(703) 379-9111
3970 Fort Worth Ave
Alexandria, VA
Specialties
Internal Medicine, Medical Oncology
Gender
Male
Education
Medical School: Georgetown Univ Sch Of Med, Washington Dc 20007
Graduation Year: 1969
Hospital
Hospital: Inova Fairfax Hospital, Falls Church, Va; Inova Alexandria Hospital, Alexandria, Va
Group Practice: Hemotology-Oncology Assoc Ltd

Data Provided by:
Mary Jean Herden, MD
119 Martin Ln
Alexandria, VA
Specialties
Oncology (Cancer)
Gender
Female
Education
Medical School: Univ Of Al Sch Of Med, Birmingham Al 35294
Graduation Year: 1983

Data Provided by:
Data Provided by:

Folotyn for Non-Hodgkin's Lymphoma

Provided By:

FRIDAY, Sept. 25 (HealthDay News) -- The drug Folotyn (pralatrexate) has been approved to treat Peripheral T-cell Lymphoma (PTCL), an often aggressive form of non-Hodgkin's lymphoma, the U.S. Food and Drug Administration said Friday.

The drug, given accelerated approval because it treats an unmet medical need, was sanctioned for people whose disease has returned or hasn't responded to other types of chemotherapy, the agency said in a news release.

PTCL strikes fewer than 9,500 people each year in the United States, the FDA said. The disease affects a type of white blood cell, called a T-cell, involved in the body's disease-fighting immune system.

Approval of Folotyn was based on clinical data showing it reduced tumor size in 27 percent of 109 people with PTCL who were studied. The most common adverse reactions included sores of the lips, mouth and digestive tract, low white blood cell counts, fever, nausea and fatigue.

Since the drug can harm a fetus, women taking Folotyn should avoid becoming pregnant, the FDA said. Anyone taking the drug should also take folate and vitamin B12 supplements to help reduce irritation of the mucous membranes.

Folotyn is produced by Colorado-based Allos Therapeutics, which is required to conduct additional studies of tumor shrinkage and life expectancy, the agency said.

More information

The FDA has more about this drug.

Copyright © 2009 ScoutNews, LLC. All rights reserved.

Read Article at HealthDay.com